Q&A Session with Dr. Robert Rosenthal, Chair of UMB’s Institutional Review Board, and Dr. Julie Doherty, Director of the Human Research Protection Program.
The session focused on providing information and answering questions related to UMB's Guidelines on Resuming Human Subject Research, including preparing for progression to Stage 1.
A Summary of the Major Provisions of the Title IX Final Rules can be found on the Office for Civil Rights, Department of Education, website at https://www2.ed.gov/about/offices/list/ocr/docs/titleix-summary.pdf.
The UMB COVID 19 Research Advisory Task Force was charged with developing guidance for restarting research considering the ongoing pandemic. This guidance provides a tiered, staged approach for resuming human subjects research activities, responding to the varied need for personal contact, physical space, and the ability to maintain personal and environmental safety precautions.
Resumption Plan - Assessment Questions
Resuming Human Subjects Research - Stage 2 Examples
GCCC Re-Open research plan FINAL
GCCC Clinical-Research-Resumption---Checklist-for-Resuming-FINAL-UMGCCC_06 30 20
HSF III User Procedure CTRIM human COVID19 v3
SON HS Research Resumption Process 7.14.20
13 May 2020, - The FDA is issuing this guidance to assist sponsors in the clinical development of drugs for the treatment or prevention of COVID-19. Click to read FDA guidance.
13 May 2020, - FDA is issuing this guidance to provide general considerations to assist sponsors in preparing pre-investigational new drug application (pre- IND) meeting requests for COVID-19 related drugs1 for the duration of the COVID-19 public health emergency. Click to read Pre-IND guidance.
11 May 2020, This section provides information on UMB’s Committees and Task Forces convened in response to the COVID-19 pandemic and human subjects research arising in response, the Biospecimen Repository being created under an umbrella protocol, COVID-19 Clinical and other Trials, and provides a FAQ for the research community.
November 4th-9th, 2019
This is a time for organizations of all types and sizes to spotlight the efforts and actions that create and reinforce a culture of compliance.
March 7th, 2019
NIH Notice: NOT-OD-19-029 - Harassment and Discrimination Protections in NIH Training Applications.
March 6th, 2019
Information and Contacts for reporting misconduct related to Discrimination or Bias.
This resource contains information and definitions from UMB’s policies and procedures related to sexual misconduct, as well as information about on-campus and off-campus resources available to UMB students. This brochure also includes risk reduction information, general information and recommendations about what to do in the immediate aftermath of a sexual assault, and UMB’s procedures for responding to sexual misconduct.
Found here: Resources and References
620 W. Lexington St.
Fifth Floor
Baltimore, MD 21201
Office hours are 8:30 a.m. to 5 p.m., Monday through Friday.
* The Office of Accountability and Compliance has returned to campus after the COVID-19 pandemic and we are ready to respond promptly to phone and email inquiries to assist our community.
The University of Maryland, Baltimore is the founding campus of the University System of Maryland.
620 W. Lexington St., Baltimore, MD
21201 | 410-706-3100
